Noam A VanderWalde1, Allison M Deal2, Elizabeth Comitz3, Lori Stravers3, Hyman Muss4, Bryce B Reeve5, Ethan Basch4, Joel Tepper3, Bhishamjit Chera3. 1. Department of Radiation Oncology, University of Tennessee Health Science Center/West Cancer Center, Germantown, Tennessee. Electronic address: nvanderw@westclinic.com. 2. Biostatistics and Clinical Data Management Core, University of North Carolina at Chapel Hill/Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. 3. Department of Radiation Oncology, University of North Carolina at Chapel Hill/Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. 4. Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill/Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina. 5. Department of Health Policy and Management, Gillings School of Global Public Health, Chapel Hill, North Carolina.
Abstract
PURPOSE: To evaluate the association between functional status based on a geriatric assessment (GA) and outcomes of tolerance to treatment in patients with lung or head and neck cancer receiving radiation therapy (RT) or chemoradiation (CRT). METHODS AND MATERIALS: A prospective cohort study was conducted in patients aged ≥65 years with head and neck cancer or lung cancer undergoing curative intent RT or CRT. Pretreatment GA, health-related quality of life (HRQoL), and patient-reported outcomes (PRO) were obtained. Questionnaires were repeated biweekly during RT and at 6 weeks after treatment. Dysfunction was defined as scores <14 on the Instrumental Activities of Daily Living scale. Poor tolerance to treatment was defined by hospitalization, >3-day treatment delay, change in RT or CRT regimen, or death. Associations of dysfunction with tolerance to radiation therapy, HRQoL changes, and PRO ratings were evaluated. RESULTS: Of the 50 patients accrued, 46 had evaluable data. Mean age was 72.5 years (range, 65-92 years). At baseline, 37% had dysfunction. Poor tolerance to RT or CRT occurred in 39%. There was no association between dysfunction and tolerance. Patients with dysfunction had lower baseline HRQoL scores. From baseline to end of RT, those with baseline dysfunction had less of a decline in Role Functioning (P=.01) and Global Health Score (P=.04) domains. However, from end of RT to 6-week follow-up, those with dysfunction were more likely to continue to drop in the Physical, Role Functioning, and Social domains (all P<.01). Dysfunction at baseline was also associated with higher severity of certain PROs. CONCLUSIONS: Pretreatment dysfunction was associated with continued decline and lack of recovery of HRQoL in this patient population. Larger studies could further elucidate the GA's predictive value.
PURPOSE: To evaluate the association between functional status based on a geriatric assessment (GA) and outcomes of tolerance to treatment in patients with lung or head and neck cancer receiving radiation therapy (RT) or chemoradiation (CRT). METHODS AND MATERIALS: A prospective cohort study was conducted in patients aged ≥65 years with head and neck cancer or lung cancer undergoing curative intent RT or CRT. Pretreatment GA, health-related quality of life (HRQoL), and patient-reported outcomes (PRO) were obtained. Questionnaires were repeated biweekly during RT and at 6 weeks after treatment. Dysfunction was defined as scores <14 on the Instrumental Activities of Daily Living scale. Poor tolerance to treatment was defined by hospitalization, >3-day treatment delay, change in RT or CRT regimen, or death. Associations of dysfunction with tolerance to radiation therapy, HRQoL changes, and PRO ratings were evaluated. RESULTS: Of the 50 patients accrued, 46 had evaluable data. Mean age was 72.5 years (range, 65-92 years). At baseline, 37% had dysfunction. Poor tolerance to RT or CRT occurred in 39%. There was no association between dysfunction and tolerance. Patients with dysfunction had lower baseline HRQoL scores. From baseline to end of RT, those with baseline dysfunction had less of a decline in Role Functioning (P=.01) and Global Health Score (P=.04) domains. However, from end of RT to 6-week follow-up, those with dysfunction were more likely to continue to drop in the Physical, Role Functioning, and Social domains (all P<.01). Dysfunction at baseline was also associated with higher severity of certain PROs. CONCLUSIONS: Pretreatment dysfunction was associated with continued decline and lack of recovery of HRQoL in this patient population. Larger studies could further elucidate the GA's predictive value.
Authors: Ronald Maggiore; Zachary S Zumsteg; Karlynn BrintzenhofeSzoc; Kelly M Trevino; Ajeet Gajra; Beatriz Korc-Grodzicki; Joel B Epstein; Stewart M Bond; Ira Parker; Julie A Kish; Barbara A Murphy; Noam A VanderWalde Journal: Int J Radiat Oncol Biol Phys Date: 2017-07-15 Impact factor: 7.038
Authors: Ryan T Morse; Rohit G Ganju; Gregory N Gan; Ying Cao; Prakash Neupane; Kiran Kakarala; Yelizaveta Shnayder; Christopher E Lominska Journal: Cancers (Basel) Date: 2022-04-22 Impact factor: 6.575
Authors: Daniel R Dickstein; Eric J Lehrer; Kristin Hsieh; Alexandra Hotca; Brianna M Jones; Ann Powers; Sonam Sharma; Jerry Liu; Vishal Gupta; Loren Mell; Zain Husain; Diana Kirke; Krzysztof Misiukiewicz; Marshall Posner; Eric Genden; Richard L Bakst Journal: Cancers (Basel) Date: 2022-06-05 Impact factor: 6.575
Authors: Jorunn Drageset; Reidun Karin Sandvik; Leslie Sofia Pareja Eide; Gunhild Austrheim; Mary Fox; Elisabeth Grov Beisland Journal: Health Qual Life Outcomes Date: 2021-03-20 Impact factor: 3.186
Authors: Erik Haehl; Alexander Rühle; Simon Spohn; Tanja Sprave; Eleni Gkika; Constantinos Zamboglou; Anca-Ligia Grosu; Nils H Nicolay Journal: Front Oncol Date: 2022-01-03 Impact factor: 6.244